atezolizumab plus bevacizumab (n=334) vs. Standard of Care (SoC) (n=334)
randomized controlled trial
atezolizumab plus bevacizumab
1200 mg intravenous atezolizumab plus intravenous bevacizumab 15 mg/kg every 3 weeks for up to 12 months or 17 cycles
active surveillance
Patients randomly allocated to active surveillance were permitted to receive crossover treatment with atezolizumab plus bevacizumabat investigator discretion on independent review facility confirmation of disease recurrence. Resection or ablation of recurrent lesions was allowed before crossover treatment.
mHCC - (neo)adjuvant (NA)
open label
34 centres in 26 countries
NCI-2018-01106, 2022 NCT03222076
nivolumab plus ipilimumab (n=14) vs. nivolumab alone (n=13)
randomized controlled trial
nivolumab plus ipilimumab
480 mg of nivolumab IV every 4 weeks plus 1 mg/kg of ipilimumab IV every 6 weeks up to 4 doses before and after surgery
nivolumab
240 mg of nivolumab intravenously (IV) every 2 weeks alone
mHCC - (neo)adjuvant (NA)
Patient can have had prior treatment for HCC including prior surgery, radiation therapy, local-regional therapy (ablation or arterial directed therapies), and systemic therapy including sorafenib or chemotherapy
open design
single-center
The goal of this arm was to study if unresectable localized disease will have adequate tumor shrinkage to become resectable.
Wang, 2024 ChiCTR2000037655
sintilimab (n=99) vs. Standard of Care (SoC) (n=99)
randomized controlled trial
sintilimab
sintilimab injections every 3 weeks for a total of eight cycles